EAM
CSTL icon

Eventide Asset Management’s Castle Biosciences CSTL Stock Holding History

Eventide Asset Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-386,425
Closed -$9.49M – 310
2026
Q1 		$9.49M Buy
386,425
+81,425
+27% +$2.67M 0.16% 143
2025
Q4 		$11.9M Buy
+305,000
New +$9.83M 0.19% 135

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Eventide Asset Management's CSTL Position: Q2 2026 in Review

Eventide Asset Management sold out of Castle Biosciences (CSTL) in Q2 2026, closing a stake of 386,425 shares — an estimated $9.49M sold.

Eventide Asset Management first reported a position in CSTL in Q4 2025 and held it in 2 quarters. The position peaked at $11.9M in Q4 2025. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Eventide Asset Management reported no remaining Castle Biosciences position as of Q2 2026 after selling out during the quarter.
  • Eventide Asset Management sold 386,425 Castle Biosciences shares in Q2 2026, an estimated $9.49M.
  • Eventide Asset Management first reported a position in Castle Biosciences in Q4 2025 and held it in 2 quarters.
  • Eventide Asset Management's Castle Biosciences position peaked at $11.9M in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.